

Biliary Tract Neoplasms Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/B0E9B4311087EN.html>

Date: May 2024

Pages: 128

Price: US\$ 6,499.00 (Single User License)

ID: B0E9B4311087EN

Abstracts

The 7 major biliary tract neoplasms markets are expected to exhibit a CAGR of 7.21% during 2024-2034.

The biliary tract neoplasms market has been comprehensively analyzed in IMARC's new report titled "Biliary Tract Neoplasms Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Biliary tract neoplasms are malignant tumors that develop in the bile duct system, which includes the gallbladder, intrahepatic bile ducts, and extrahepatic bile ducts. These tumors are relatively rare but can be aggressive, significantly impacting the flow of bile, which aids in the digestion of fats. The symptoms of this ailment often mimic various other gastrointestinal disorders, making early diagnosis challenging. Common indications include jaundice, abdominal pain, unexplained weight loss, changes in stool and urine color, itching, etc. As the tumors progress, they can obstruct bile flow, leading to the aforementioned symptoms and potential complications. The diagnosis of biliary tract neoplasms involves a combination of imaging techniques, such as ultrasound, computed tomography scans, magnetic resonance imaging (MRI), and endoscopic retrograde cholangiopancreatography (ERCP). Tissue samples for a definitive diagnosis are obtained through procedures like fine-needle aspiration (FNA) or tissue biopsy. Additionally, blood tests measuring liver function and tumor markers are also recommended for patients.

The escalating prevalence of chronic inflammation of the bile ducts, that can cause cellular damage and promote the development of abnormal cells, is primarily driving the biliary tract neoplasms market. In addition to this, the inflating utilization of efficacious therapeutic interventions, including surgical resections, chemotherapy, and radiation,

designed to effectively manage the ailment and impede its progression, is also creating a positive outlook for the market. Moreover, the widespread adoption of supportive therapies and palliative care options aimed at enhancing the quality of life for patients by mitigating symptoms and addressing discomfort is further bolstering the market growth. Apart from this, the rising usage of minimally invasive procedures like laparoscopy and endoscopic interventions, which offer reduced postoperative complications and quicker recovery periods, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of immunotherapies and targeted therapies, since they harness the body's immune response to combat neoplastic growth in individuals suffering from the illness, is also augmenting the market growth. Furthermore, the ongoing research in the field of molecular biology, including the launch of gene therapy approaches that aim at introducing or modifying genetic material within cells to inhibit the growth of cancerous cells, is expected to drive the biliary tract neoplasms market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the biliary tract neoplasms market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for biliary tract neoplasms and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the biliary tract neoplasms market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the biliary tract neoplasms market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the biliary tract neoplasms market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current biliary tract neoplasms marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Biliary Tract Neoplasms Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast...

Market Insights

How has the biliary tract neoplasms market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the biliary tract neoplasms market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the biliary tract neoplasms market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of biliary tract neoplasms across the seven major markets?

What is the number of prevalent cases (2018-2034) of biliary tract neoplasms by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of biliary tract neoplasms by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with biliary tract neoplasms across the seven major markets?

What is the size of the biliary tract neoplasms patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of biliary tract neoplasms?

What will be the growth rate of patients across the seven major markets?

Biliary Tract Neoplasms: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for biliary tract neoplasms drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the biliary tract neoplasms market?

What are the key regulatory events related to the biliary tract neoplasms market?

What is the structure of clinical trial landscape by status related to the biliary tract neoplasms market?

What is the structure of clinical trial landscape by phase related to the biliary tract neoplasms market?

What is the structure of clinical trial landscape by route of administration related to the biliary tract neoplasms market?

Contents

?1 Preface

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 BILIARY TRACT NEOPLASMS - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (???2018-2023?) and Forecast (2024-2034)
- 4.4 Market Overview (???2018-2023?) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 BILIARY TRACT NEOPLASMS - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 BILIARY TRACT NEOPLASMS - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (???2018-2023?)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (??2018-2034)
 - 7.2.4 Epidemiology by Gender (??2018-2034)
 - 7.2.5 Diagnosed Cases (??2018-2034)
 - 7.2.6 Patient Pool/Treated Cases (??2018-2034)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (???2018-2023?)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (??2018-2034)
 - 7.3.4 Epidemiology by Gender (??2018-2034)
 - 7.3.5 Diagnosed Cases (??2018-2034)
 - 7.3.6 Patient Pool/Treated Cases (??2018-2034)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (???2018-2023?)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (??2018-2034)
 - 7.4.4 Epidemiology by Gender (??2018-2034)
 - 7.4.5 Diagnosed Cases (??2018-2034)
 - 7.4.6 Patient Pool/Treated Cases (??2018-2034)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (???2018-2023?)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (??2018-2034)
 - 7.5.4 Epidemiology by Gender (??2018-2034)
 - 7.5.5 Diagnosed Cases (??2018-2034)
 - 7.5.6 Patient Pool/Treated Cases (??2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (???2018-2023?)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (??2018-2034)
 - 7.6.4 Epidemiology by Gender (??2018-2034)
 - 7.6.5 Diagnosed Cases (??2018-2034)
 - 7.6.6 Patient Pool/Treated Cases (??2018-2034)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (???2018-2023?)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (??2018-2034)

- 7.7.4 Epidemiology by Gender (??2018-2034)
- 7.7.5 Diagnosed Cases (??2018-2034)
- 7.7.6 Patient Pool/Treated Cases (??2018-2034)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (???2018-2023?)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (??2018-2034)
 - 7.8.4 Epidemiology by Gender (??2018-2034)
 - 7.8.5 Diagnosed Cases (??2018-2034)
 - 7.8.6 Patient Pool/Treated Cases (??2018-2034)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (???2018-2023?)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (??2018-2034)
 - 7.9.4 Epidemiology by Gender (??2018-2034)
 - 7.9.5 Diagnosed Cases (??2018-2034)
 - 7.9.6 Patient Pool/Treated Cases (??2018-2034)

8 BILIARY TRACT NEOPLASMS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 BILIARY TRACT NEOPLASMS - UNMET NEEDS

10 BILIARY TRACT NEOPLASMS - KEY ENDPOINTS OF TREATMENT

11 BILIARY TRACT NEOPLASMS - MARKETED PRODUCTS

- 11.1 List of Biliary Tract Neoplasms Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Imfinzi (Durvalumab) - Celgene/MedImmune
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets
 - 11.1.2 Lytgobi (Futibatinib) - Taiho Oncology/Taiho Pharmaceutical
 - 11.1.2.1 Drug Overview

- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets
- 11.1.3 Pemazyre (Pemigatinib) - Incyte Corporation
 - 11.1.3.1 Drug Overview
 - 11.1.3.2 Mechanism of Action
 - 11.1.3.3 Regulatory Status
 - 11.1.3.4 Clinical Trial Results
 - 11.1.3.5 Sales Across Major Markets
- 11.1.4 Tibsovo (Ivosidenib) - Servier
 - 11.1.4.1 Drug Overview
 - 11.1.4.2 Mechanism of Action
 - 11.1.4.3 Regulatory Status
 - 11.1.4.4 Clinical Trial Results
 - 11.1.4.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 BILIARY TRACT NEOPLASMS - PIPELINE DRUGS

- 12.1 List of Biliary Tract Neoplasms Pipeline Drugs Across the Top 7 Markets
 - 12.1.1 CAN04 - Cantargia AB
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action
 - 12.1.1.3 Clinical Trial Results
 - 12.1.1.4 Safety and Efficacy
 - 12.1.1.5 Regulatory Status
 - 12.1.2 AVA6000 - Avacta Life Sciences
 - 12.1.2.1 Drug Overview
 - 12.1.2.2 Mechanism of Action
 - 12.1.2.3 Clinical Trial Results
 - 12.1.2.4 Safety and Efficacy
 - 12.1.2.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13 BILIARY TRACT NEOPLASMS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14 BILIARY TRACT NEOPLASMS – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 BILIARY TRACT NEOPLASMS - MARKET SCENARIO

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
 - 15.2.1 Biliary Tract Neoplasms - Market Size
 - 15.2.1.1 Market Size (???2018-2023?)
 - 15.2.1.2 Market Forecast (2024-2034)
 - 15.2.2 Biliary Tract Neoplasms - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (???2018-2023?)
 - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
 - 15.3.1 Biliary Tract Neoplasms - Market Size
 - 15.3.1.1 Market Size (???2018-2023?)
 - 15.3.1.2 Market Forecast (2024-2034)
 - 15.3.2 Biliary Tract Neoplasms - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (???2018-2023?)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
 - 15.3.3 Biliary Tract Neoplasms - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Biliary Tract Neoplasms - Market Size
 - 15.4.1.1 Market Size (???2018-2023?)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Biliary Tract Neoplasms - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (???2018-2023?)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Biliary Tract Neoplasms - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Biliary Tract Neoplasms - Market Size
 - 15.5.1.1 Market Size (???2018-2023?)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Biliary Tract Neoplasms - Market Size by Therapies

- 15.5.2.1 Market Size by Therapies (???2018-2023?)
- 15.5.2.2 Market Forecast by Therapies (2024-2034)
- 15.5.3 Biliary Tract Neoplasms - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Biliary Tract Neoplasms - Market Size
 - 15.6.1.1 Market Size (???2018-2023?)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Biliary Tract Neoplasms - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (???2018-2023?)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Biliary Tract Neoplasms - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Biliary Tract Neoplasms - Market Size
 - 15.7.1.1 Market Size (???2018-2023?)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Biliary Tract Neoplasms - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (???2018-2023?)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Biliary Tract Neoplasms - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Biliary Tract Neoplasms - Market Size
 - 15.8.1.1 Market Size (???2018-2023?)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Biliary Tract Neoplasms - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (???2018-2023?)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Biliary Tract Neoplasms - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Biliary Tract Neoplasms - Market Size
 - 15.9.1.1 Market Size (???2018-2023?)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Biliary Tract Neoplasms - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (???2018-2023?)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Biliary Tract Neoplasms - Access and Reimbursement Overview

16 BILIARY TRACT NEOPLASMS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 BILIARY TRACT NEOPLASMS MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 BILIARY TRACT NEOPLASMS MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Biliary Tract Neoplasms Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/B0E9B4311087EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B0E9B4311087EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

